en · de · es · fr · pt
creatine-notes.peptides4800.com › Info › Tb-500 Identity And Chemical Background — Questions and Answers

Tb-500 Identity And Chemical Background — Questions and Answers

By Editorial Desk · published 2025-11-07 · last reviewed 2025-11-24 · Info

freeze-dried powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-11-24. Anything still debated is marked as such rather than presented as settled.

TB-500 Identity and Chemical Background

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Identity and Physical Form

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

Tb-500 at a glance

PropertyValueNotes
Physical formLyophilised powderSealed vial; reconstituted before laboratory use
AppearanceWhite to off-white solidVisual descriptor used on certificates of analysis
Solubility classWater-solubleDissolves in water and aqueous buffers
Reported mass, fragmentNear 889 DaValue depends on the stated sequence
Reported mass, parent proteinNear 4963 Da43-residue thymosin beta-4

Identity and Research Background

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Related pages on this site

TB-500 Identity and Naming Background

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

Thymosin Beta-4 Fragment Identity

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

Detection, Stability, and Regulatory Status

Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.

Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

Supporting material

== Experimental techniques == Since the original experiments by Geoffrey Harris investigating the communication of the hypothalamus with the pituitary gland, much has been learned about the mechanistic details of this interaction. Various experimental techniques have been employed. Early experiments relied heavily on the electrophysiology techniques used by Hodgkin and Huxley. Recent approaches have incorporated various mathematical models to understand previously identified mechanisms and predict systemic response and adaptation under various circumstances.

2 CH3CH=CH2 + 3 O2 + 2 NH3 → 2 N≡CCH=CH2 + 6 H2O In the production of acrylonitrile, a side product is acetonitrile. On an industrial scale, several derivatives of benzonitrile, phthalonitrile, as well as Isobutyronitrile are prepared by ammoxidation. The process is catalysed by metal oxides and is assumed to proceed via the imine. Ammoxidation is a heterogeneously catalyzed gas-phase reaction in which aliphatic or methyl-substituted aromatic compounds react with oxygen (air) and ammonia to form nitriles, with water as a by-product. Reaction temperatures exceed 300 °C, and oxides of vanadium, chromium, or molybdenum serve as catalysts. Acrylonitrile, an important precursor for polymer production (see Use section), is primarily manufactured by ammoxidation of propene. The principal industrial route to hydrogen cyanide is the Andrussov process, i.e., ammoxidation of methane over a platinum catalyst. However, a significant proportion of global hydrogen cyanide production arises as a by-product of acrylonitrile manufacture.

Although the following examples illustrate the diversity of point-mutation–mediated disorders, there are over 300,000 such mutations recorded in HGMD and over 1,000,000 variants in ClinVar, reflecting the vast spectrum of human point mutations.

== Principle == An HID connected to a gas chromatograph (GC) has the great advantage to use helium as both the carrier gas and the ionization gas. An HID is an ion detector which uses a radioactive source, typically β-emitters, to create metastable helium species. The radioactive source ionizes helium atoms by bombarding them with emissions. The metastable helium species have an energy of up to 19.8 eV. These metastable helium species can ionize all compounds with the exception of neon which has a greater ionization potential of 21.56 eV. As components elute from the GC's column they collide with the metastable helium ions, which then ionize the components. The ions produce an electric current, which is the signal output of the detector. The greater the concentration of the component, the more ions are produced, and the greater the current.

Sources: en.wikipedia.org

Supporting material

==== Benzoctamine and sodium amylobarbitone ==== In a study used to compare benzoctamine to sodium amylobarbitone as a sleep promoter, it was found that during administration of both drugs, patients reported that their sleep was less restless, and drowsiness was diminished. The study further showed that while sodium amylobarbitone caused withdrawal rebound symptoms, benzoctamine did not. It was also found that benzoctamine reduced plasma corticosteroid hormone levels. There is a relationship between anxiety and adreno-corticosteroid activity, with raised levels commonly being reported as an indication of stress. The study showed that benzoctamine, a drug reported to reduce anxiety, was also able to reduce the hormones that potentially cause it. This points to a phenomenon often seen within pharmacology where drugs intended for other uses often have far-reaching and rarely considered effects.

=== As an invasive species === Although listed as an invasive species in several countries, one source reports that M. oleifera has "not been observed invading intact habitats or displacing native flora", so "should be regarded at present as a widely cultivated species with low invasive potential."

Malabar had been traditionally used to denote the west coast of Southern India that forms the present-day state of Kerala and adjoining areas. The word mala or malaya means "mountain" in the Tamil and Malayalam languages, as also in Sanskrit. The word "malabathrum" is thought to have been derived from the Sanskrit tamālapattram (तमालपत्त्रम्), literally meaning "dark-tree leaves".

For services to the community in Radley, Oxfordshire. Robert Frank Earl. For services to the community in Radley, Oxfordshire. Christopher Harry Wrenn Eaton. For services to the community in Wakes Colne, Essex. Euros Hefin Edwards. Watch Manager, Mid and West Wales Fire and Rescue Service. For services to Fire and Rescue. Greta Edwards. Cleaner and Kitchen Assistant, North Shore Academy, Stockton-on-Tees. For services to Education. Llinos Edwards. Lately Nurse Team Leader, The Looked After Children Team, Betsi Cadwaladr University Health Board. For services to Vulnerable Children in North Wales. Stephen David Elsden. Chief Executive, Compaid Trust. For services to Charity and to People with Disabilities. Robert Felix Erith TD DL. For services to the Environment in Dedham Vale, Essex and Suffolk. Sandra Mary Esqulant. For services to the community in Spitalfields, London Borough of Tower Hamlets. Annabel Whyte Evans. For services to the community in Chesham, Buckinghamshire. Lyndsey Claire Evans. For services to the community in South Wye, Herefordshire. Marian Louise Evans. For services to Business. Edward Everett. Member, Friends of Bridgwater Canal. For services to the Environment in Sale, Metropolitan Borough of Trafford. John Fielding. Scout Leader, 2nd Rishton Baptist Scout Group, Lancashire. For services to Young People and to the community in Lancashire. Mabel Elsie Finnigan. County Captain, Shropshire Ladies Bowls Team. For services to Bowls. Mary Margaret Rose Fisher. Lately Lollipop Crossing Patrol, Darley and Summerbridge Community Primary School, Harrogate.

=== Overbilling the government === In 1992, the company was one of the first to be prosecuted as part of Operation Labscam, a nationwide crackdown on fraud in the healthcare system initiated by the U.S. Attorney's Office in San Diego, California. The company and others were accused of routinely submitting false claims to Medicare and Medicaid for unnecessary tests on blood samples that physicians had never ordered. In addition, charges for the tests billed to the government were significantly higher than what the company charged private insurers. That year, the company agreed to pay $111 million to settle claims. In November 1996, the company agreed to pay a total of $182 million as a result of the investigation. In February 2023, the company paid $19 million to resolve allegations that it violated the False Claims Act of 1863 by its submission of false claims to Medicare.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.

Why do product listings show different sequences?

Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.

What is the reported molecular mass?

The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.

Is TB-500 the same substance as thymosin beta-4?

Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.

Network